Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Acute Leukemia in Remission: early-phase trial registry
1 of 2 indexed Acute Leukemia in Remission trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Acute Leukemia in Remission: 2 US clinical trials tracked, 1 recruiting.
Acute Leukemia in Remission is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is University of Michigan Rogel Cancer Center, running 1 of these trials.
Enrollment posture brief
Registry condition acute-leukemia-in-remission
OPEN 1 | RECR 50% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Acute Leukemia in Remission lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Acute Leukemia in Remission on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Acute Leukemia in Remission is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues
University of Chicago
NCT06171152
Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
University of Michigan Rogel Cancer Center
NCT03842696
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Acute Leukemia in Remission records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Acute Leukemia in Remission trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Acute Leukemia in Remission page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Acute Leukemia in Remission trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Michigan Rogel Cancer Center sponsors the most Acute Leukemia in Remission trials on record, review their full trial history before evaluating a specific study. See University of Michigan Rogel Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Acute Leukemia in Remission condition card totals 2 registered trials; most-linked intervention Tacrolimus (or cyclosporine); top US site state Wisconsin. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.